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A B S T R A C T
The use of biological tissues in the in vitro assessments of dissolving (?) microneedle (MN) array
mechanical strength and subsequent drug release proﬁles presents some fundamental difﬁculties, in part
due to inherent variability of the biological tissues employed. As a result, these biological materials are
not appropriate for routine used in industrial formulation development or quality control (QC) tests. In
the present work a facile system using Paraﬁlm M1 (PF) to test drug permeation performance using
dissolving MN arrays is proposed. Dissolving MN arrays containing 196 needles (600 mm needle height)
were inserted into a single layer of PF and a hermetic “pouch” was created including the array inside. The
resulting system was placed in a dissolution bath and the release of model molecules was evaluated.
Different MN formulations were tested using this novel setup, releasing between 40 and 180 mg of their
cargos after 6 h. The proposed system is a more realistic approach for MN testing than the typical
performance test described in the literature for conventional transdermal patches. Additionally, the use
of PF membrane was tested either in the hermetic “pouch” and using Franz Cell methodology yielding
comparable release curves. Microscopy was used in order to ascertain the insertion of the different MN
arrays in the PF layer. The proposed system appears to be a good alternative to the use of Franz cells in
order to compare different MN formulations. Given the increasing industrial interest in MN technology,
the proposed system has potential as a standardised drug/active agent release test for quality control
purposes.
ã 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Microneedle (MN) devices are currently attracting great
interest in transdermal drug/vaccine delivery and patient moni-
toring (Donnelly et al., 2014a, 2012b; Mooney et al., 2014; Prausnitz
2004; Quinn et al., 2014; Yang et al., 2013). These systems are
composed of an array of micron-sized needles that painlessly, and
without drawing blood, pierce and bypass the outermost layer of
the skin, the stratum corneum (SC), which is the principal barrier to
transdermal drug delivery (Benson and Watkinson, 2012; Hadgraft,
2002; Prausnitz et al., 2004). MN arrays create micro-conduits
through the SC that can be used to deliver drugs to the deeper
layers of the skin from where they can be absorbed directly into the* Corresponding author at: Chair in Pharmaceutical Technology, School of
Pharmacy, Queens University Belfast, Medical Biology Centre, 97 Lisburn Road,
Belfast BT9 7BL, UK. Fax: +44 28 90 247 794.
E-mail address: r.donnelly@qub.ac.uk (R.F. Donnelly).
http://dx.doi.org/10.1016/j.ijpharm.2015.11.038
0378-5173/ã 2015 The Authors. Published by Elsevier B.V. This is an open access articsystemic circulation, or to deliver vaccines to the skin-resident
antigen-presenting cells (Donnelly et al., 2012b; Tuan-Mahmood
et al., 2013).
MN technology is, of course, part of the broader transdermal
drug delivery (TDD) area. TDD has been an important area of
pharmaceutical research and development over the last four
decades (Margetts and Sawyer, 2007; Prausnitz et al., 2004;
Prausnitz and Langer, 2008). More recently, the market value of
TDD has increased signiﬁcantly from US$12.7 billion dollars in
2005 to an expected US$32 billion in 2015 (Paudel et al., 2010).
However, this market is predominantly based on passive diffusion
through the SC. This limits the number of molecules to only a small
group (less than 20 approved drugs) that share three features:
molecular mass <500 Da, relatively high lipophilicity and low
required daily dose (<2 mg) (Margetts and Sawyer, 2007). As MN
arrays bypass the SC, molecules delivered using this technology do
not need to fulﬁl these requirements (Donnelly et al., 2012b). This
makes MN technology an appealing approach to overcome the
main limitations of conventional transdermal delivery systemsle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Composition of different formulations (%w/w).
Compound F1 F2 F3 F4
Gantrez1 S-97 20.0 20.0 – –
PEG 10,000 7.50 7.50 – –
PVP 58 kDa – – – 40.00
PVA 9-10 kDa – – 20.00 –
Methylene blue 0.50 – 0.37 0.73
FITC-Dextran 70 kDa – 1.00 – –
Water 72.00 71.50 – 59.27
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avoidance of the ﬁrst-pass effect, suitability for self-administration
and prolonged drug release (Prausnitz and Langer, 2008). MN
mediated transdermal drug delivery offers a major expansion of
the route.
To date there are no MN transdermal patches on the market due
to the difﬁculty in scale-up of fabrication (Lutton et al., 2015a). In
addition, there are no currently accepted regulatory standards for
MN products. The lack of MN regulation generates further
difﬁculties regarding mass production, which requires accepted
standards to assess product quality (Lutton et al., 2015a).
To date, almost all MN insertion and drug permeation studies
have been carried out using biological tissue. A variety of skin
models, such as heat separated epidermis, dermatomed skin, full-
thickness skin, in addition to synthetic membranes have been used
for these purposes (Coulman et al., 2009; Garland et al., 2012; Lee
et al., 2008; Verbaan et al., 2007). Biological tissue samples are
often heterogeneous, unstable, difﬁcult to obtain and the use of
biological materials sometimes presents legal issues. Therefore,
these biological materials are not suitable to be routinely used in
industrial formulation development or quality control (QC) tests as
the tests themselves are not reproducible and, accordingly, cannot
be transferred between laboratories. A good alternative to
overcome these limitations in MN testing is to replace biological
tissues with synthetic materials. The number of research
publications detailing the use of artiﬁcial membranes in MN
testing is limited however. Some examples of studies outlining the
use of artiﬁcial membranes for MN insertion studies are:
(Hamilton, 2011; Koelmans et al., 2013; Larrañeta et al., 2014;
Muthu, 2007). Drug permeation studies using artiﬁcial membranes
have been carried out by the following research teams (Donnelly
et al., 2009; Garland et al., 2012; Zhang et al., 2014). Garland et al.
(2012) studied the use of different skin models, including
biological tissue (dermatomed and full-thickness neonatal porcine
skin) and an artiﬁcial silicone membrane (Silescol1), to evaluate
drug permeation from dissolving MN arrays. Due to the elasticity of
the Silescol1membrane, MN arrays did not remain inserted in the
membrane but rather were withdrawn from it, thus limiting drug
permeation. For this reason, Silescol1 membranes cannot be
considered a suitable material for MN testing.
In the past, we proposed the use of Paraﬁlm M1 as a model for
MN insertion studies (Larrañeta et al., 2014). Continuing with the
use of artiﬁcial membranes for MN characterization/testing in this
work, a facile method using Paraﬁlm M1 to test drug permeation
using dissolving MN arrays is proposed. A series of dissolving MN
arrays were prepared containing representative models of either a
low molecular weight active (methylene blue) or a macromolecule
(ﬂuorescein isothiocyanate–dextran). Permeation of these mole-
cules was evaluated in vitro using the proposed method and
compared with conventional Franz cells permeation experiments.
2. Material and Methods
2.1. Materials
Gantrez1 S-97 (Mw= 1,500.000), a copolymer of methylviny-
lether and maleic acid polymers, was provided by Ashland (Surrey,
UK). Poly(ethyleneglycol) (PEG, Mw= 10,000), poly(vinyl alcohol)
(PVA, Mw= 9000–10,000, 80% hydrolyzed) and Methylene blue
were obtained from Sigma–Aldrich (Dorset, UK). The
isothiocyanate–dextran (FITC-dextran 70, Mw= 63,00077,000)
was obtained from TdB Consultancy AB (Uppsala, Sweden) and
polyvinylpyrrolidone (PVP, Mw= 58,000) was obtained from Ash-
land (Surrey, UK). Paraﬁlm1 M, a ﬂexible thermoplastic sheet
(127 mm thickness) made of oleﬁn-type material was obtained
from Brand GMBH (Wertheim, Germany).2.2. Mehtods
2.2.1. Preparation of MN arrays
Aqueous blends containing Gantrez1 S-97 (20% w/w), PEG
10,000 (7.5% w/w) and the selected molecules were individually
used to fabricate MN arrays. Table 1 shows the formulations used
in this study. This formulation was poured into laser-engineered
silicone micromould templates, centrifuged for 15 min at
3500 rpm, allowed to dry under ambient conditions for 48 h. This
process was followed for the preparation of dissolving MN arrays.
In order to prepare hydrogel-forming MN arrays, a crosslinking
step (80 C for 24 h) was carried out after the MN arrays were dry
(Donnelly et al., 2012a,2014b). Additionally the hydrogel-forming
MN arrays formulation only containing Gantrez1 S-97 and PEG
10,000. All the arrays (1 cm2) contained 14 14 needles with the
following dimensions: 600 mm needle height and 300 mm width at
the base.
2.2.2. Release experiments
MN arrays were inserted in a single PF layer using a TA.XTPlus
Texture Analyser (Stable Micro Systems, Surrey, UK) in compres-
sion mode (Larrañeta et al., 2014). MN arrays were placed on the
surface of the PF membrane and the probe lowered onto the MN
array at a speed of 0.5 mm s1 until the required force was exerted
(40 N). Forces were held for 30 s. Once the target force was reached,
the probe was moved upwards at a speed of 0.5 mm s1. PF was
then folded around the baseplate of the MN array and thermally
sealed, thus creating a hermetic “pouch” (Fig. 1A). A UK twenty
pence coin was applied to the back part of the system as sinker
(Diameter = 21.4 mm; Weight = 5.0 g; Thickness = 1.7 mm; Compo-
sition: 84% copper and 16% nickel) was applied to the back part of
the system. The experiment was slightly modiﬁed for the release of
hydrogel-forming MN arrays. This speciﬁc type of MN arrays was
inserted in the PF and the backing layer containing MB was
attached to the baseplate (Donnelly et al., 2012a). The diffusion of
water will cause controlled swelling of the MN arrays creating an in
situ hydrogel conduit. This will allow the liberation and diffusion of
MB from the patch through the hydrogel MN into the release
medium (Donnelly et al., 2012a). The release experiment was
carried out by placing two of these closed PF/MN array systems
inside a beaker containing 30 mL of phosphate buffer solution (PBS,
pH 7.4) (Fig.1B) in a thermostatic bath at 32 C with a stirring speed
of 52 strokes/min). Samples (1 mL) were extracted at deﬁned time
intervals and replaced with an equal volume of PBS.
2.2.3. Franz cell permeation studies
A single layer of PF was placed on a sheet of dental wax and then
a MN array was inserted into the PF using a TA.XT-plus Texture
Analyser (Stable Micro Systems, Surrey, UK) as described before.
The PF sheet with the MN arrays inserted was placed and secured
to the donor compartment of the diffusion cell using cynoacrylate
adhesive. Once MN arrays were in place, donor compartments
were mounted onto the receptor compartments of the Franz cells
Fig. 1. Diagrams of the insertion and preparation of the PF hermetic “pouch” (A). Diagram of the hermetic “pouch” release experiments (B). Diagram of the Franz Cell system
used for the permeation experiment (C).
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compartment at 37 C to bring the skin surface temperature to
32 C (Sarmento, 2015). The patch and the MN array were kept in
place during the experiment by application of a metallic weight to
their upper surface. Using a long needle, samples (0.2–0.3 mL)
were extracted from the receptor compartment at deﬁned time
intervals and replaced with an equal volume of receptor medium.
The concentration of the selected molecule in the receiver
compartment was determined using UV–vis spectroscopy. The
Franz Cell system is shown in Fig. 1C.
2.2.4. UV–vis and ﬂuorescence quantiﬁcation methods
Methylene blue samples were analysed using a UV–vis plate
reader (PowerWave XS Microplate Spectrophotometer, Bio-Tek,
Winooski, USA) at a wavelength of 664 nm.
FITC-Dextran samples were analysed using a ﬂuorescence plate
reader (BMG FLUOstar OPTIMA Microplate Reader, BMG Labtech,
Ortenberg, Germany) with 493 nm and 520 nm as excitation and
emission wavelengths, respectively.
Calibration curves were obtained in quintuplicate with each
calibration curve contained a minimum of 8 data points. Least
squares linear regression analysis and correlation analysis were
performed on the obtained calibration curves (Table 2). The limit of
detection (LoD) of each method was determined as follows, using
Eq. (1):
LoD ¼ 3:3  s
S
ð1ÞTable 2
Calibration curves properties of methylene blue and FITC-Dextran as determined by
linear regression and correlation analysis, LoD and LoQ.
Molecule Slope y-
Intercept
r2 LoD (mg/
ml)
LoQ (mg/ml)
Methylene blue 0.13 0.04 0.996 0.21 0.63
FITC-Dextran
70 kDa
1012.00 37.39 0.998 0.30 0.91where s is the standard error of the regression line and S is the
slope of that line. Similarly, the limit of quantiﬁcation (LoQ) was
determined using Eq. (2):
LoQ ¼ 10  s
S
ð2Þ
2.2.5. Microscopy and optical coherence tomography (OCT)
Microscopy images were obtained using a Leica EZ4 D digital
microscope (Leica, Wetzlar, Germany) and a Keyence VHX-700F
Digital Microscope equipped with a VH-Z20R lens (Keyence, Osaka,
Japan). OCT images were recorder using an EX1301 OCT Micro-
scope (Michelson Diagnostics Ltd., Kent, UK) and analysed using
the imaging software ImageJ1 (National Institutes of Health,
Bethesda, USA).
3. Results
Fig. 2 shows pictures of MN arrays produced using the
formulations described in Table 1. All the produced arrays present
consistently formed needles. Fig. 3A shows the release of MB from
F1 MN arrays and baseplates using the hermetic “pouch”
experimental system. Only MN arrays exhibited a release proﬁle.
This fact points out that the designed system is hermetic and only
allows release from MN arrays that pierce it. The initial points of
the release proﬁle were not taken into account as the MB
concentration in the release medium was below the LoQ of the
system. If the release experiment was performed in a Franz cell
setup, but using PF instead of biological tissue (Fig. 3B) the
obtained results are similar to those obtained using the hermetic
“pouch” setup. The shape of the release proﬁles for both
experimental designs suggests that there are two steps involved
in the process. Over the course of the ﬁrst 30 min of experimenta-
tion, there was a burst release of MB, while after this time interval a
more sustained release process took place. The ﬁrst process is
likely to be due to the dissolution of the needle tips that were in
contact with the release medium (PBS). Once the tips were
dissolved the created holes in the PF allowed the permeation of PBS
inside the pouch, allowing the dissolution of the baseplates and the
Fig. 2. Microscopy images of 14 14 MN arrays made using F1 (A), F2 (B), F3 (C) and F4 (D).
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phenomena was observed for the Franz Cells system and this can
be explained in a similar fashion. The holes created in the PF
membrane allow PBS to permeate into the baseplate surface, thusFig. 3. MB release from F1 14 14 MN arrays and baseplates through PF using the
hermetic “pouch” setup (A). The dashed line shows the limit of quantiﬁcation (LoQ).
MB release from F114 14 MN arrays and baseplates through PF using the hermetic
“pouch” and Franz cell setups (B). Means  standard deviation, n = 3.dissolving it. In order to investigate this phenomenon microscopy
and OCT images of the release system were taken at different times
of the release experiments (Fig. 4). In these pictures the evolution
of the needle tips can be observed. It is noticeable that after 90 min
the needle tip that was exposed to the release medium is totally
dissolved. Furthermore, in the last pictures (120 min) it can be seen
that the created holes were not closing. All these observations are
consistent with the previous hypothesis. Therefore, it can be
concluded that the release mechanism involves the dissolution of
the needle tips and, subsequently, the permeation of the release
ﬂuid inside the “pouch”. It is noteworthy that the hermetic “pouch”
approach requires the use of two MN arrays whereas those
involving Franz Cell apparatus only require one MN array. In
addition, the volume of release medium required for the hermetic
“pouch” experimental setup was greater than that required for
Franz Cell experiments. As a result and in order to obtain
quantiﬁable drug levels, above the LoQ of the system, two MN
arrays were used in this experimental design.
In addition to small molecules, the system was used to evaluate
the release of a macromolecule using the same type of MN arrays.
Fig. 5A shows the release of ﬂuorescent-labelled dextran (FITC-
dextran 70 kDa) using F2 MN arrays through the hermetic “pouch”
release system. The release proﬁle showed a very similar shape to
those obtained for MB. Fig. 5B shows the comparison of the
percentage of MB and FITC-dextran released from F1 and F2 MN
arrays, respectively. The comparison was made using percentage
rather than cumulative amount of the model molecule due to the
different loading for both formulations (Table 1). F2 samples were
prepared using a higher loading of the model molecule as the
detection/quantiﬁcation limits for the FITC-dextran analytical
method were higher than for MB. Both curves can be considered
equivalent. Similar to that observed in MB release experiments, the
release of FITC-dextran over the course of the ﬁrst 15 min was not
taken into account when analysing experimental results as the
concentration of the compound in the release medium was below
the LoQ of the system.
The novel release system was used to evaluate the release of MB
from different polymeric dissolving MN arrays. Fig. 6A shows the
release of MB from F3 (PVA) and F1 (Gantrez S97 + PEG 10.000).
Fig. 4. OCT (left) and microscopy (right) images of F1 14 14 MN arrays inserted in PF at different stages of the release experiment. Images obtained using an EX1301 OCT
Microscope and a Keyence VHX-700F Digital Microscope.
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release than that of F1 but it must be noted that all MB
concentrations in the release medium derived from F3 were
below the LoQ of the system. After 60 min, the release of MB from
F3 MN arrays accelerated. Following 90 min MB concentrationsFig. 5. FITC-dextran release from F2 14 14 MN arrays through PF using the
hermetic “pouch” setup (A). The dashed line shows the limit of quantiﬁcation (LoQ).
Comparison between FITC-dextran and MB release from F1 and F2 14 14 MN
arrays through PF using the hermetic “pouch” setup (B). Means  standard
deviation, n = 3.were above the LoQ and after 180 min the concentration of MB
released was superior to that determined for the F1 MN arrays. The
different permeation proﬁle may be explained by the different
chemical nature of the polymers. It is well known that PVA has the
ability to swell partially before its dissolution (Harland et al., 1988;
Quintanar-Guerrero et al., 1999). This fact could also be responsible
for the slow MB release during the ﬁrst hour of the experiment.
Additionally, the different nature of the polymer could change the
mechanical properties of the arrays, thereby affecting MN
insertion. Fig. 7A and B shows the insertion of MN arrays in PF.
It is noticeable that the insertion of the needles in the PF layer is not
as good as for F1 MN arrays.
When a different polymer to PVP or Gantrez1 was used to
produce MN arrays again different release proﬁle can be observed.
Fig. 6B shows the release proﬁle of MB from F4 (PVP) MN arrays. In
this case MB release was more sustained than that of F1 over the
course of the experiment. Quantiﬁable levels of MB were only
obtained after 240 min. The selected PVP present poor mechanical
properties yielding MN with really brittle baseplates that can be
fractured during insertion affecting MN insertion. This can be
observed in Fig. 7C that shows a picture of F4 MN arrays inserted in
PF. As can be seen MN pierced the polyoleﬁn layer but the needles
did not remain inserted properly.
4. Discussion
One of the key challenges for MN technology is the scale-up of
manufacturing technologies. Nowadays, a certain number of MN-
based products are being developed by different companies
(Anon., 2015a,b; Matriano et al., 2002; Zhang et al., 2012).
However, the lack of speciﬁc quality standards and deﬁned
speciﬁcations for this novel dosage form are some of the
predominant challenges facing industrial scale manufacture of
MN arrays. According to the International Conference on Harmo-
nisation: “A speciﬁcation is deﬁned as a list of tests, references to
analytical procedures, and appropriate acceptance criteria, which are
numerical limits, ranges, or other criteria for the tests described”
Fig. 6. MB release from F1 and F3 dissolving 14 14 MN arrays through PF using the
hermetic “pouch” (A). MB release from F1 and F4 dissolving 14 14 MN arrays
through PF using the hermetic “pouch” (B). Means  standard deviation, n = 3.
Fig. 7. Microscopy images of F3 (A and B) and F4 (C) 14 14 MN arrays inserted in PF
before the release experiment. Images obtained using an EX1301 OCT Microscope
and a Keyence VHX-700F Digital Microscope.
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MNs, the basic requirements of the technology must be identiﬁed
and deﬁned. To this end, the basic requirements of MN arrays are to
puncture the skin, be inserted, remain intact or dissolve (depend-
ing on the MN type) while delivering their cargo and ﬁnally to be
removed intact (solid MN) or devoid of needle tips (dissolving MN)
within the appropriate time scale. To the date, only a few studies
evaluating some of these quality control/product speciﬁcation
considerations have been reported and they have mainly focused
on the insertion and mechanical properties of the MN systems
(Larrañeta et al., 2014,2015; Lutton et al., 2015a,b).
The in vitro testing of drug release is a key evaluation for the
development of drug delivery and quality control systems. To the
date, traditional transdermal patches can be tested following
different product performance tests described by the US Pharma-
copeia (Ueda et al., 2009). The simplest test consists of release
testing of the transdermal patch inside a USP Apparatus following
the ‘Paddle over Disk’ Method (Ueda et al., 2009). This test
evaluates the release of the drug loaded in the patch from the
entire surface of the patch. However, dissolving MN arrays have a
different mechanism of action. The needles located in the surface
of the array pierce the SC allowing the drug located in the needle to
be released once the polymeric matrix is dissolved/biodegraded in
the viable skin layers (Donnelly et al., 2012b; Prausnitz, 2004).
Therefore, the USP product performance test does not reﬂect the
MN mechanism of action. This is an example that highlights the
need for new quality standards designed speciﬁcally for MN
products.
Recently, Larrañeta et al. proposed the use of a polymeric ﬁlm as
a model for MN insertion studies (Larrañeta et al., 2014). In this
work it was shown that Paraﬁlm M1 can be used as a skin simulant
for MN insertion showing good correlation with the results
obtained using excised porcine skin, considered a good model for
human skin (Kong and Bhargava, 2011). The present work can be
considered a continuation of that study, proposing the use of thesame material to design a release test that can be easily
standardised as a quality control test for MN.
Initially, two different approaches were carried out using
Paraﬁlm M1: a Franz Cell system and a hermetic “pouch” system
(Fig. 1). As can be seen in Fig. 3, both systems yield equivalent
release proﬁles of the model molecule (methylene blue). Therefore,
both appear to be valid as methods to evaluate drug release from
dissolving MN arrays. Additionally, different formulations were
evaluated using the hermetic “pouch” approach. This facile system
was selected as it is less complex than the use of Franz Diffusion
Cells. In addition to MB, the release of a larger model molecule
from the dissolving MN arrays was evaluated (Fig. 5). It was
noticeable that both release proﬁles can be considered equivalent.
Fig. 8. Hydrogel-forming MN arrays breaking PF hermetic “pouch” during swelling.
Images obtained using a Leica EZ4 D digital microscope.
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polymeric matrix containing the model molecules.
The release test was able to differentiate the release proﬁles of
different formulations. Fig. 6 shows the release of PVA and PVP MN
arrays loaded with MB. As explained above, different polymers will
have different mechanical and chemical properties that will
inﬂuence the release process. The proposed performance test is a
good alternative to evaluate these differences.
In the past, artiﬁcial silicone membranes were used to evaluate
drug release from MN arrays (Donnelly et al., 2009; Garland et al.,
2012). In the case of Silescol1membranes, the elastic nature of the
membrane forced the MN arrays to retract after insertion and
consequently the needle tips did not reside within the created
micropores, thus yielding incomplete drug release proﬁles. In
contrast, PF does not present the same limitation, as can be seen in
Figs. 4 and 7. In this case the MN tips can be seen inserted and
located inside the created micropores.
As explained above the described hermetic “pouch” system
presented promising results to be used as performance test of
dissolving MN arrays. We also attempted to apply the same test to
hydrogel forming MN arrays. However, as can be seen in Fig. 8, this
type of MN arrays could not be used in combination with the
hermetic “pouch”. During the expansion process of the arrays the
PF layer was broken. Hence, this method can be used mainly for
dissolving and possibly coated MN arrays.
In addition to quality control, the proposed method would
prove to be a good option in comparing different types of
dissolving MN arrays during the formulation development phase.
As pharmaceutical companies strive to shorten product develop-
ment times, straightforward tests such as this could prove to beinvaluable. The proposed test is capable of evaluating in vitro drug
release from dissolving MN arrays, allowing the analyst to assess
the mechanism that governs the drug release proﬁle. Knowing the
key parameters and the release mechanism of a particular drug
delivery system is essential for formulation development, espe-
cially in early phases were limited amounts of drug may be
available. The release of active pharmaceutical ingredients from
dissolving MN arrays is mainly governed by the dissolution of the
MN matrix (Donnelly et al., 2012b; Prausnitz, 2004). Using the
proposed PF setup, the use of different types of polymers in the
formulation of the MN arrays led to vastly different drug release
proﬁles that could be related back to the different solubility
behaviours of the employed polymers. The test therefore fulﬁls one
of the most important requirements for this type of test in that it is
capable of discriminating differences between different formula-
tions.
To conclude, the annotated methodology is complementary to
one described previously to predict MN insertion capabilities
(Larrañeta et al., 2014) thus allowing the in vitro testing of two key
aspects of MN technology for transdermal drug delivery, namely,
MN insertion efﬁciency and drug release proﬁle.
5. Conclusion
The lack of known and established product speciﬁcations is one
of the main problems for MN manufacture. Universal acceptance
criteria for MN speciﬁcations should be agreed by MN researchers.
As MN arrays are drug delivery systems, it is clear that a release/
dissolution speciﬁcation should be included. Therefore, the
proposed test seem to be a good alternative to cover this gap. It
allows direct comparisons and, therefore, provides a quick
diagnostic method to test successfully manufactured MNs. Besides,
the test is facile, reliable, does not require expensive/complex
equipment. This, it has the potential to test new types of MN arrays
during formulation development stages. Additionally, it can
complement existing techniques/protocols widely used for the
physical characterization of MN arrays.
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